Jazz Pharmaceuticals to Acquire Chimerix in $935M Deal

Jazz Pharmaceuticals has announced its acquisition of Chimerix in a $935 million all-cash deal, strengthening its rare oncology portfolio. This strategic move brings Chimerix’s lead clinical asset, dordaviprone, into Jazz’s pipeline—a promising first-in-class treatment for H3 K27M-mutant diffuse glioma, a rare and aggressive brain tumor. With no current FDA-approved therapies for this condition, dordaviprone could become a groundbreaking treatment if approved, potentially setting a new standard of care. The acquisition, approved by both companies, is expected to close in Q2 2025, with a potential U.S. commercial launch in the near term.

The FDA has granted Priority Review to dordaviprone’s New Drug Application (NDA) for treating recurrent cases, with a PDUFA target action date of August 18, 2025. Jazz aims to leverage its development and commercialization expertise to accelerate access to the therapy. “This acquisition reinforces our commitment to addressing unmet needs in rare oncology,” said Jazz CEO Bruce Cozadd. Chimerix CEO Mike Andriole echoed this sentiment, highlighting the opportunity to expand dordaviprone’s reach to more patients globally. The deal also secures durable revenue potential for Jazz, with patent protection extending into 2037.